Skip to main content

Prestigious publication confirms potential of technology used by Karolinska Development’s portfolio company OssDsign

Written by Customer Service on . Posted in Public Companies.

STOCKHOLM, SWEDEN – October 14, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that a scientific article describing the portfolio company OssDsign’s unique regenerative implants has been published in the reputable scientific journal PNAS (Proceedings of the National Academy of Sciences of the United States). The article describes how OssDsign’s implant concept and patented material composition contribute to bone regeneration and adhesion with existing bone.The research article reports a plurality of pre-clinical data from the use of OssDsign’s implant concept in an animal model. The findings are further corroborated through clinical data in the form of analysis of an implant that was explanted from a patient due to trauma 21 months post implantation.The published research results describe the capacity of OssDsign’s implant concept and proprietary ceramic material to regenerate and restore large cranial defects with mature bone, with a morphology, ultrastructure, and composition similar to those of native skull bone. These results are in line with previously published clinical data from the use of OssDsign’s implant technology.The article, headlined “In situ bone regeneration of large cranial defects using synthetic ceramic implants with a tailored composition and design”, is available under Open Access at the PNAS website: https://www.pnas.org/content/early/2020/10/06/2007635117For further information, please contact:Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.comFredrik Järrsten, CFO and deputy CEO, Karolinska Development AB
Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.comTO THE EDITORSAbout Karolinska Development AB

 Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.For more information, please visit www.karolinskadevelopment.comAttachmentKD PR OssDsign 2020-10-14 ENG

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.